African Cluster

Developed by AstraZeneca and implemented across Africa in collaboration with African Governments and Non-Governmental Organizations (NGOs), Healthy Heart Africa (HHA) is designed to contribute to the prevention and control of hypertension and decreasing the burden of cardiovascular disease (CVD) across Africa.  Launched in Kenya in 2014, Ethiopia in 2016, Tanzania in 2018, Ghana in 2019, Uganda in 2020 and Côte d'Ivoire, Senegal and Rwanda in 2021, and Nigeria and Zanzibar in 2022, the programme supports sustainable models by working with local health systems.  Each model works independently with partners in the country of implementation to address different health challenges and health environments, with the aim of providing a sustainable means of fighting hypertension in Africa.

In support of the United Nations targets to reduce the risk of premature death from NCDs[1]  along with the Pan-African Society of Cardiology (PASCAR) ‘Roadmap’ to reduce heart disease and stroke [2],  HHA aspires to reach 10 million people with elevated blood pressure by 2025, working together with local and global partners to support local health systems by:

·         Increasing awareness of the symptoms and risks of hypertension

·         Training providers and driving care to the lower levels of the healthcare system

·         Offering health education, screening, and reduced-cost treatment and control, as applicable.

In 2016, AstraZeneca and PEPFAR partnered to use hypertension as a stigma-free entry point to find and reach those who need HIV services by integrating hypertension services into existing HIV platforms. It expanded access to HIV/AIDS and hypertension services by offering them in an integrated manner at existing PEPFAR-supported HIV/AIDS sites.

More information on Healthy Heart Africa can be found here.

[1]R. L. Sacco et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke. Circulation. 2016, 11:e674-e690. Available at:  http://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed August 2023.

2 A. Dzudie et al. PASCAR Roadmap on Hypertension. Roadmap to achieve 25% hypertension control in Africa by 2025. Cardiovascular Journal of Africa. 2017. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642030/pdf/cvja-28-262.pdf Last accessed August 2023.

Our award-winning AstraZeneca Young Health Programme has a unique focus on young people and primary prevention of the most common non-communicable diseases (NCDs). Working in partnership with global and local organisations, the Young Health Programme works to positively impact the health of adolescents through research, evidence generation, advocacy for change and on-the-ground programmes. The Young Health Programme was launched in Kenya in partnership with Plan International in 2016 and aims to contribute to improved health and gender equality of Nairobi’s Kibera and Mathare informal settlements.

In South Africa and Angola the Young Health Programme partnership with UNICEF aims to catalyse a global advocacy movement led by young people for the promotion of healthier lifestyles. The focus is on raising awareness of key issues, empowering young people to advocate, and taking policy action to create meaningful and lasting change.

More information about the Young Health Programme can be found here. 
 

YHP Impact Fellowship

The Young Health Programme (YHP) Impact Fellowship provides grants to help small, innovative, youth-focused non-profits develop and deliver effective health promotion programmes, with an emphasis on under-resourced and marginalised communities in low and middle-income countries.

Young leaders, called YHP Impact Fellows, who are managing the delivery and implementation of these projects are supported through the Fellowship with access to development and networks to help them scale their impact even further.

More information on the YHP Impact Fellowship,   our African Fellows and their projects can be found here.  

Cancer Care Africa  represents AstraZeneca’s commitment to co-creating a stronger and sustainable cancer care ecosystem in Africa, together with external partners, that help to close the gaps in the existing patient care pathway, from diagnosis through to treatment and beyond. 

Launched in November 2022 at COP27 in Egypt, CCA aids countries in their fight against cancer by focusing on 4 pillars of impact: build capacity & capabilities, enhance screening & diagnostics, focus on patient empowerment, and enable access to medicines.

Taking a country-by-country approach, we are bringing together cancer experts, researchers, patient voices, health tech firms, government officials and policymakers, aiming to develop sustainable cancer care ecosystems which can withstand the burden of future pressures.

Our collaboration with Aga Khan University in Kenya, supports the installation of eGFR (estimated glomerular filtration rate) testing, paving the way for efficient, cost-effective testing in Kenya, and drastically reducing response times.

Cancer Care Africa is also encouraging countries to share best-practice and other expertise across borders to the benefit of all. The Preceptorship programmes aim to uplift multi-disciplinary oncology medical capabilities and so far, have been delivered for lung and prostate cancer and have connected expertise from Kenya and Egypt for cross-border education, knowledge exchange and practical training.

As we strive for a healthier future, we must collaborate to transform the future of healthcare and improve the lives of people living in Africa – we must act now in Africa, for Africa.  

More information on our Cancer Care Africa programme is available here

In Kenya the MP Shah Hospital is the first hospital in Africa to join the CaReMe Global Alliance spearheaded by AstraZeneca, aimed at improving outcomes for patients with cardiovascular, renal, and metabolic (CVRM) diseases, including conditions like diabetes, heart failure and chronic kidney disease.

In South Africa AstraZeneca has partnered with BrandMed a leading South African connected healthcare company that integrates medical and lifestyle expertise and science with ground-breaking technologies. As part of this collaboration AstraZeneca has provided sponsorship towards the establishment of fifteen BrandMed Syntro-P Health Centres of Excellence offering patients access to a more proactive, patient-centric, integrated risk-reduction and treatment approach to chronic conditions.

In 2023, AstraZeneca launched the pioneering Africa Health Innovation Hub to increase access to quality healthcare across the continent, utilising the latest science and technology. 

The Africa Health Innovation Hub is part of the global A.Catalyst Network, a connected array of over 20 hubs worldwide. This network seeks to tackle current healthcare challenges through collaborative innovation, promote affordable and equitable healthcare access, and amplify patient-centred innovation through strategic alliances within the healthcare ecosystem.  

AstraZeneca reinforces its commitment through several partnerships. Globally, AstraZeneca forms part of the WEF Edison Alliance, highlighting the role of technology and data in enhancing healthcare access, focusing on patient-centric solutions and digital inclusion as vital components for healthcare equity.

In Africa, the following new partnerships form the backbone of the Africa Innovation Hub in its initial phases:  

• In South Africa, AstraZeneca is partnering with Medsol AI to help develop Melusi Breast AI, a state-of-the-art Wi-Fi ultrasound probe.  The AI device supports  screening and detection of  lesions at risk of breast cancer in a matter of seconds and is being introduced into primary care clinics. The device offers virtual connectivity to experts, expediting early screening and diagnosis  and prompt treatment initiation. This innovative approach is set potentially truncate screening-diagnosis-to-treatment time by 50%, delivering a pivotal first point of contact for patients. 
• In Kenya, we are expanding an already successful collaboration with Tricog Health Limited. After a few years of piloting in India, the African hub aims to enhance early diagnosis and treatment of Heart Failure using Tricog’s InstaECG AI tools for rapid diagnosis, reducing mortality rates and improving quality of life. 
• Our partnership with Qure AI in South Africa and Kenya, employs AI to scrutinize X-rays to spot potential lung cancer indicators. This proactive approach, identifying high risk lung lesions with 88% accuracy, empowers early treatment and successful outcomes.
• Partnering with Futurize, A.Catalyst supports the Fuel Africa and FuturizeU initiatives.
  • Fuel Africa is the largest healthcare entrepreneurship programme on the Continent, bringing together the brightest minds across universities in Sub-Saharan Africa to address some of Africa’s most pressing challenges in healthcare.
  • FuturizeU is a new pioneering healthtech incubator programme empowering the upcoming generation of healthcare entrepreneurs with essential tools for navigating startup complexities. The program fosters groundbreaking solutions, addressing vital healthcare access and early non-communicable disease (NCD) diagnosis challenges across Africa. Leveraging cutting-edge technology like AI and machine learning (ML), FuturizeU accelerates meaningful healthcare advancements while nurturing a fertile ground for innovation.

More information about the A. Catalyst network can be found here.  

Phakamisa v/t [phaga’mi:sa]: IsiZulu for elevate, lift, raise, uplift, upliftment.

Through partnerships with multiple healthcare stakeholders in South Africa we aim to improve the health outcomes for patients and reduce the burden of non-communicable diseases on South Africa’s public healthcare system. Phakamisa specifically addresses early detection of disease, promotion of primary prevention, capability building and access to care.

In collaboration with the Lung Ambition Alliance,  the programme is continually evolving, responsive to the needs identified in public healthcare. In 2023, Phakamisa expanded from its focus on Breast and Prostate Cancer, to include all AstraZeneca focus therapeutic areas, and is exploring the potential for AI-driven diagnostics and healthcare innovation in oncology.

Phakamisa, which means ‘to uplift’ in Zulu, is delivered through a three-pillared approach:

• Training –  supporting healthcare worker capacity building across all levels of care, from Primary Care Clinics and Community Healthcare Centres to District and Tertiary Hospitals, to ensure effective diagnosis and enhanced referral systems. 
• Awareness – raising awareness to empower patients, community healthcare workers and healthcare professionals of NCDs with a focus on breast self-examination, identification, improved referral timelines that result in early diagnosis and timeous intervention and care for better treatment outcomes.
• Access – ensuring that patients are able to access clinics early with minimal pit stops within the referral pathway, providing adequate access to care before the progression of the disease.

My.Phakamisa

PUMUA is a Swahili word that means ‘Breathe’

The Africa PUMUA Initiative is AstraZeneca's innovative programme committed to Redefining Asthma Care in Africa. Through partnership with Governments, Healthcare Professionals and Societies, and AstraZeneca, the Initiative aims to improve paediatric and adult asthma management across public and private sectors with a focus on:

• Local health system strengthening
• Health worker capacity building
• Awareness and education
• Equitable access to AstraZeneca’s respiratory medicines

The Initiative forms part of AstraZeneca’s sustainability commitment to deliver improved accessibility, acceptability, affordability and availability of quality care in Africa.

Our Yes2PUMUA patient support website offers a valuable resource for people living with asthma, providing tools, information, and support.

The site is more than just accessible information, it offers an extension of care that reaches beyond the consulting room and offers practical support plans and downloadable resources.

Click the link and explore : Yes2PUMUA.com - redefining Asthma Care in Africa

Our patient support websites offer a valuable resource for people living with asthma, Cardio-Renal and Metabolic diseases (CVRM), providing tools, information, and support.

The sites are more than just accessible information, they offer an extension of care that reaches beyond the consulting room and offers practical support plans and downloadable resources.

Click the links and explore

• Yes2Life – Understanding and treating cardiovascular, renal, and metabolic diseases as interlinked conditions
• Yes2Breathe.co.za – Understanding Asthma
• Yes2PUMUA.com – redefining Asthma Care in Africa
• Yes2Nurture  – RSV support for caregivers of young patients

 

Who is Responsible for Your Personal Data

In this Privacy Notice, “AstraZeneca’’, ‘’We’’, ‘’Us’’ and ‘’Our’’ refers to the AstraZeneca group companies.

We determine the purposes and manner in which your personal data is collected, used and/or disclosed and managed in line with AstraZeneca’s internal global privacy standards

AstraZeneca takes the privacy and security of your personal data very seriously. This Privacy Notice outlines the categories of personal data We may collect about you and how We may use it.

We may change this Privacy Notice from time to time. We will notify you of any changes where We are required to do so.

What Information Do We Collect and How Do We Use It?

If you register to use this website, or complete an online form, or send Us an email (e.g. to obtain email updates or ask Us to send you further information and/or to send you invitations to participate in scientific meetings, promotional events, cooperation opportunities and surveys), then We may collect and use personal data about you such as:

• Name
• Email address
• Country of residence
• Address
• Telephone number
• Occupation (for example, if you are a Healthcare Professional seeking information about our products)
• Technical information about your device, such as your IP address, device type, device and advertising identifiers, browser type and version, and other standard server log information
• Other personal data you choose to provide to Us

Such information will be provided by you and may be supplemented by Us from publicly available information or data brokers where appropriate. It is used by Us in our legitimate interests to administer the website, register you for any services you have signed up to and respond to any queries or requests for information you may have.

Occasionally, We may obtain sensitive personal data about you, for example, if you voluntarily provide information about your physical or mental health, as part of a request for information. In this case, We use such information only to respond to your inquiry and if applicable to provide you additional guidance (e.g. to inform you of your right to submit an adverse event report). By providing Us with your sensitive personal data, you consent to Us processing this data for the purposes set out in this Privacy Notice or any collection notice provided to you.

In the event you use this website, or complete an online form, or send Us an email to report an adverse event you have experienced whilst taking an AstraZeneca product, please review the adverse event reporting notice for your relevant country, available via http://aereporting.mmmukg.com to get further information on how We process your personal data in relation to adverse events.

Cookies and Do-Not-Track Signals

We may also collect information about how you use the website using cookies (and other similar technologies), as part of improving the content and functionality of the website. For more information about the use of cookies please see the cookie notice on the webpage. AstraZeneca does not respond to Do-Not-Track Signals.

Aggregate Information

We use aggregate information, which does not identify individuals, to monitor customer traffic patterns to the website and particular pages, as well as site usage, in order to help us improve the design and layout of the content.

Who Will Have Access To Your Personal Data?

Your personal data may be transferred to other AstraZeneca group companies. We may also share categories of your personal data listed above with certain service providers or third parties such as: IT providers for the purposes of system development and technical support; auditors and consultants to verify our compliance with external and internal requirements; statutory bodies, law enforcement agencies and litigants, as per a legal reporting requirement or claim; and a successor or business partner to AstraZeneca or to an AstraZeneca group company in the event that it sells, divests or sets up a collaboration/joint venture for all or part of its business.

How do We Store Your Data

AstraZeneca will store your personal data for a number of years in accordance with local laws and the company´s Document Retention Policy. For more information on AstraZeneca's internal Document Retention policy you may go to www.astrazenecapersonaldataretention.com

International Transfer

AstraZeneca entities and third parties may be based anywhere in the world, which could include countries that may not offer the same legal protections for personal data as your country of residence. Irrespective of which country your personal data is transferred to, We would only share your personal data under a strict ‘need to know’ basis and under appropriate contractual restrictions (such as AstraZeneca’s Binding Corporate Rules and EU Standard Contract Clauses). You may request a copy of AstraZeneca’s Binding Corporate Rules and/or AstraZeneca’s EU Standard Contract Clauses by contacting AstraZeneca at privacy@mmmukg.com.

Binding Corporate Rules

We have ensured compliance with some of Our legal obligations in relation to personal data by creating a set of ‘Binding Corporate Rules’ (BCRs). The BCRs set out AstraZeneca’s data privacy commitments in respect of personal data that is transferred internationally.

You can find out more about these commitments here. The BCRs and any rights arising under them do not apply to personal data originating in the U.S.A.

How We Protect Your Information

We have in place appropriate privacy and security policies which are intended to ensure, as far as reasonably possible, the security and integrity of all Our information, including your personal data.

More information on how AstraZeneca complies with its data privacy obligations can be found in our internal global privacy standards.

What are Your Rights You may contact AstraZeneca at www.astrazenecapersonaldataretention.com at any time to request information on how We process your personal data, access to the personal data We hold about you, to correct any mistakes or to request deletion of the same or withdraw your consent to certain types of processing of your personal data. If such a request places AstraZeneca or its affiliates in breach of its obligations under applicable laws, regulations or codes of practice, then AstraZeneca may not be able to comply with your request, but you may still be able to request that We block (i.e. right to object) the use of your personal information for further processing. Subject to applicable law, you may also have a right to data portability to another data controller under certain circumstances which would involve the sharing of your data with the controller in an electronic format. Subject to applicable law, you can exercise these rights for free.

AstraZeneca has assigned a data protection officer responsible for overseeing AstraZeneca’s compliance with EU and UK data protection laws, which you may contact at privacy@mmmukg.com or by mail at the Global Data Protection Officer, Astra Zeneca Middlewood Court, Silk Road, Macclesfield, Cheshire SK10 2NA, in case of any questions or concerns regarding the processing of your personal data. If AstraZeneca’s processing of your personal data is covered by EU or UK law, you can also lodge a complaint with the corresponding data protection supervisory authority in your country of residence. You can find the relevant EU supervisory authority name and contact details under http://edpb.europa.eu/about-edpb/board/members_en and the UK data protection supervisory authority’s contact details under http://ico.org.uk/global/contact-us/.

If your information is being processed in South Africa, you have the right to lodge a complaint to the Information Regulator (established in terms of section 39 of The Protection of Personal Information Act, No. 4 of 2013) whose details can be found at the following website: http://www.justice.gov.za/inforeg/), where you allege that the processing of your personal information by AstraZeneca interferes with the protection of such personal information. Please notify AstraZeneca’s Deputy Information Officer for South Africa (at reshma.singh@mmmukg.com) to the extent that such a complaint is lodged so that AstraZeneca may stop processing the personal information during any investigation to take place by the Information Regulator.

Opting Out Of Further Communications From Us

If you have elected to receive information about Our products or services, or those of other AstraZeneca companies and wish to opt-out of receiving such information, then you can do so by sending an email to privacyrequests@mmmukg.com. You should clearly state on all communications: your name, username (if any), registration details (if any) and the name of this website.